Linked by Thom Holwerda on Mon 12th Mar 2012 19:04 UTC
Thread beginning with comment 510379
To view parent comment, click here.
To read all comments associated with this story, please click here.
To view parent comment, click here.
To read all comments associated with this story, please click here.
Features
Linked by Thom Holwerda on 05/18/13 21:33 UTC
Linked by David Adams on 05/16/13 4:23 UTC
Linked by Thom Holwerda on 05/11/13 21:41 UTC
Linked by Thom Holwerda on 05/08/13 14:22 UTC
Linked by Thom Holwerda on 05/02/13 15:28 UTC
Linked by Thom Holwerda on 04/29/13 21:06 UTC
Linked by Thom Holwerda on 04/24/13 22:24 UTC
Linked by Thom Holwerda on 04/18/13 11:21 UTC
Linked by Thom Holwerda on 04/16/13 9:29 UTC
Linked by Thom Holwerda on 04/15/13 22:44 UTC
More Features »
Sponsored Links



Member since:
2006-02-01
Yes, especially since the current system encourage to release new medicine that are not necessarily an improvement over existing medicine, since patented medicine means huge profit, while unpatented medicine means a lot of "generic", and low profit. So it is better for companies to replace medicine whose patent are expiring, with new patented medicine.